44518
document
Relief of periorbital pain after acute angle closure glaucoma attack by botulinum toxin type A . PURPOSE To assess the efficacy and safety of botulinum toxin type A ( BoNT-A ) injection in patients suffering from intractable periorbital pain after acute angle closure glaucoma ( AACG ) . PATIENTS AND METHODS In this prospective randomized intervention study , 19 patients suffering from periorbital pain after an AACG attack were injected with BoNT-A or placebo for pain relief . Patients were assessed on days 1 , 2 , 7 , 14 , 30 , 60 , and 90 . The main outcomes were mean change of visual analog rating scale ( VARS ) and index scores measured through a quality-of-life questionnaire ( EQ-5D ) , and changes in the visual analog scale ( VAS ) , all of which were assessed at each visit . A secondary outcome was the frequency and nature of adverse events and the number of patients who withdrew from the study as a result . RESULTS In the treatment group ( n=10 ) , the mean index score of EQ-5D and VAS changed significantly from the placebo group ( by 0.299 and 2.61 , respectively ) from day 2 ( P < 0.01 ) . The VARS of EQ-5D also disclosed significant changes from day 2 ( 17 , P < 0.01 ) . In addition , efficacy was maintained mainly between days 2 and 60 but declined slightly by day 90 . The most frequently reported treatment-related adverse events in the treatment and placebo groups were local tenderness ( 21 % ) , subcutaneous hemorrhage ( 10.5 % ) , and conjunctivitis ( 10.5 % ) . No severe adverse events were reported during the study or follow-up period . CONCLUSIONS BoNT-A is effective and well tolerated for the treatment of periorbital pain after an AACG attack . Its effects may be maintained for 3 months .
44519
Intervention_Pharmacological
botulinum toxin type A .
44520
Intervention_Pharmacological
botulinum toxin type A ( BoNT-A )
44521
Intervention_Pharmacological
BoNT-A
44522
Intervention_Control
placebo
44523
Intervention_Control
placebo
44524
Intervention_Pharmacological
BoNT-A
44525
Outcome_Other
visual analog scale
44526
Outcome_Other
mean index score of EQ-5D
44527
Outcome_Other
VAS
44528
Outcome_Other
VARS
44529
Outcome_Physical
of
44530
Outcome_Other
EQ-5D
44531
Outcome_Other
efficacy
44532
Outcome_Physical
local tenderness
44533
Outcome_Physical
subcutaneous hemorrhage
44534
Outcome_Physical
conjunctivitis
44535
Outcome_Adverse-effects
severe adverse events
44536
Participant_Condition
intractable periorbital pain
44537
Participant_Condition
acute angle closure glaucoma
44538
Participant_Sample-size
19
44539
Participant_Condition
AACG